MAGI3 and nonpapillary renal cell carcinoma: Notably, in stage I ccRCC patients, M/L MAGI3 expression (<261.5 RPKM) correlated with markedly reduced 10-year OS (45.5% vs. 74.6%), PFS (55% vs. 69.8%), and DSS (77.9% vs. 98%) compared to high MAGI3 expression (Fig. 1G–J, Supplementary Table 2).